Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aldeyra Therapeu
(NQ:
ALDX
)
4.160
-0.050 (-1.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aldeyra Therapeu
< Previous
1
2
3
4
5
6
Next >
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma
July 20, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes
July 01, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
May 27, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights
May 06, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2021 Financial Results and Discuss Recent Business Highlights
April 29, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
April 28, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics, Inc. Announces Proposed $125 Million Public Offering of Common Stock
April 27, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis
April 27, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE Clinical Trial
April 26, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.